[Treatment difficulties in ocular toxoplasmosis].
OBJECTIVE
To determine the increased incidence of ocular infection with Toxoplasma gondii, the variety of ocular manifestations and therapeutical problems of this potential blind disease. We analyzed 22 patients hospitalized in our clinic in last 2 years at whom clinical diagnosis was confirmed by positive serological tests. Is discussed the correlation between serum level antibody(IgG and IgM) and ocular manifestations and the opportunity of beginning specific treatment depend on these two parameters.


CONCLUSIONS
The incidence of ocular toxoplasmosis is increasingly, the ophthalmologist must be open on atypical manifestations of this disease. The treatment remains controversial, we believe that it must be specific and correlated with ocular lesions evolutions and serum antibody level in time.
Stanila
Adriana
A
Spitalul Clinic Judeţean Sibiu-Secţia Oftalmologie.
Popa
Dorina E
DE
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D003049:Coccidiostats / Q000627:therapeutic use*; D003196:Computer Graphics; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011739:Pyrimethamine / Q000627:therapeutic use; D012189:Retrospective Studies; D015572:Spiramycin / Q000627:therapeutic use*; D014126:Toxoplasmosis, Ocular / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000981:Antiprotozoal Agents; D003049:Coccidiostats; D015572:Spiramycin; D011739:Pyrimethamine